ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis

Company Overview

ADVANZ PHARMA is a specialty pharmaceutical company focused on the development, acquisition, licensing and commercialization of complex medicines and established pharmaceutical products. The company serves patients in areas where treatment options may be limited, with an emphasis on specialty, hospital and rare-disease therapies.

Its portfolio includes branded medicines, generic products and niche treatments across therapeutic categories such as neurology, gastroenterology, ophthalmology, allergy and critical care. ADVANZ PHARMA’s activities include regulatory support, supply-chain management and commercialization, allowing it to provide medicines to healthcare providers and patients without relying solely on new drug discovery.

The company is headquartered in London and operates through international markets, with products distributed across Europe and other regions. ADVANZ PHARMA was formerly known as Concordia International and adopted its current name as part of a broader strategic repositioning toward specialty and complex pharmaceuticals.

Key Stats

• Today's Range: $17.06 to $17.06
• 50-Day Range: $17.06 to $17.06
• 52-Week Range: $2.13 to $18.00
• Volume: 39 shs
• Average Volume: 11,851 shs
• Market Capitalization: $834.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CXRXF
• CIK: N/A
• Web: www.concordiarx.com
• Phone: 44-20-8588-9100
• Fax: N/A
• Employees: 429
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.86 million
• Net Margins: -15.31%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -4.38%

Debt

• Debt-to-Equity Ratio: 257.04
• Current Ratio: 2.39
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: $525.58 million
• Price / Sales: 1.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.16 per share
• Price / Book: 106.63

Miscellaneous

• Outstanding Shares: 48,913,000
• Free Float: N/A
• Market Cap: $834.46 million
• Optionable: Not Optionable
• Beta: N/A